Quality Assurance and Medicine Safety

Module Code: PHA7051-B
Academic Year: 2018-19
Credit Rating: 20
School: School of Pharmacy and Medical Sciences
Subject Area: Pharmacy
FHEQ Level: FHEQ Level 7 (Masters)

Pre-requisites:
Co-requisites:

Contact Hours

<table>
<thead>
<tr>
<th>Type</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Independent Study</td>
<td>14</td>
</tr>
<tr>
<td>Lectures</td>
<td>34</td>
</tr>
<tr>
<td>Tutorials</td>
<td>8</td>
</tr>
<tr>
<td>Directed Study</td>
<td>144</td>
</tr>
</tbody>
</table>

Availability Periods

<table>
<thead>
<tr>
<th>Occurrence</th>
<th>Location/Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>BDA</td>
<td>University of Bradford / Semester 1 (Sep - Jan)</td>
</tr>
</tbody>
</table>

Module Aims

To provide the students with the opportunity to develop their knowledge & understanding of the principles of Quality Assurance (QA), Quality Control (QC) & Good Manufacturing Practice (GMP) necessary for assuring & managing product quality in the manufacture of medicines. To provide the students with the opportunity to develop their knowledge & understanding of current regulatory procedures in the licensing of medicines, WHO guidelines for emergency medicine donation & medicines donated to resource-limited countries, the concepts of modern instrumental analysis & the monitoring of the content of medicines.

Outline Syllabus
(a) Introduction to QA systems; principles of global QA and QC, Good Pharmaceutical Manufacturing Practice; the ICH guidelines and key managerial issues for the pharmaceutical industry. (b) Sterilisation processes for pharmaceuticals. (c) The role of International pharmacopoeia standards and monographs in medicine control and protecting public health; ICH guidelines for using analytical method validation in QC. (d) Systems for regulatory control of drugs: the Licensing authorities, ICH requirements, centralised and decentralised procedures. (e) Requirements for Pharmaceutical Products Licence approval: development of a drug registration dossier. (f) Regulatory issues associated with off-license, paediatric and orphan drugs, counterfeiting, natural products and homeopathic medicines and links with 'NICE'. (g) Quality assurance of donated medicines: shelf-life, presentation, packaging and labelling (h) Advanced topics in pharmaceutical analysis, focusing on modern analytical techniques.

Cont from Aims quality of medicines during processing & at the final product stage.

**Module Learning Outcomes**

*On successful completion of this module, students will be able to...*

1. Assess, evaluate and describe with critical awareness the principles of the QA, QC and GMP systems necessary for assuring product quality in the manufacture of medicines.

2. Critically evaluate current regulatory procedures in the licensing of medicines and the development of International Harmonisation, and how they affect a developing country.

3. Analyse with critical awareness complex, incomplete or contradictory QA or regulatory data and formulate appropriate solutions.

4. Critically assess and evaluate the uses of modern analytical techniques in determining the quality of medicines both during processing and at the final product stage.

5. Devise a protocol for the assay of a compound in view of its chemical structure.

6. Analyse with critical awareness scientific research methods and develop capabilities to conduct research into QA and regulatory issues.

7. Employ verbal and written communication skills.

8. Employ team-working skills and the ability to evaluate individual contributions to group processes.

**Learning, Teaching and Assessment Strategy**

Learning outcomes 1 and 2 will be developed through a series of lead lectures supported by tutorial and discussion sessions. The students will be encouraged to examine the current guidelines and regulations in their home country and discuss how these will link with international harmonisation guidelines. Learning outcome 3 will be developed through small case studies of typical problem areas in QA (illustrated by film). Learning outcomes 3 and 4 will be developed through discussion sessions and syndicate workshops, followed by a short report and group presentations on key QA issues. Learning outcomes 5-8 will be
developed through tutorials, independent studies and small group-learning opportunities; by conducting a small project on a drug profile, followed by group discussions and presentations. Learning outcomes 1-2 will be assessed via summative examination. Learning outcomes 1, 2, and 3-8 will be assessed via coursework: the presentation and a case study report.

**Mode of Assessment**

<table>
<thead>
<tr>
<th>Type</th>
<th>Method</th>
<th>Description</th>
<th>Length</th>
<th>Weighting</th>
<th>Final Assess'</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summative</td>
<td>Examination - closed book</td>
<td>Written examination</td>
<td>2 hours</td>
<td>70%</td>
<td>Yes</td>
</tr>
<tr>
<td>Summative</td>
<td>Coursework</td>
<td>Case study report</td>
<td>1500 words</td>
<td>20%</td>
<td>No</td>
</tr>
<tr>
<td>Summative</td>
<td>Coursework</td>
<td>Oral presentation</td>
<td></td>
<td>10%</td>
<td>No</td>
</tr>
</tbody>
</table>

**Legacy Code (if applicable)**

PH-7001D

**Reading List**

To view Reading List, please go to [rebus:list](#).